PV3B Stock Overview
A clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
EyePoint Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$12.53 |
| 52 Week High | US$28.60 |
| 52 Week Low | US$5.40 |
| Beta | 1.59 |
| 11 Month Change | 62.24% |
| 3 Month Change | 49.36% |
| 1 Year Change | 73.96% |
| 33 Year Change | -5.11% |
| 5 Year Change | 9.87% |
| Change since IPO | -45.54% |
Recent News & Updates
Recent updates
Shareholder Returns
| PV3B | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0% | -2.4% | -2.2% |
| 1Y | 74.0% | -13.3% | 13.3% |
Return vs Industry: PV3B exceeded the German Pharmaceuticals industry which returned -13.3% over the past year.
Return vs Market: PV3B exceeded the German Market which returned 13.3% over the past year.
Price Volatility
| PV3B volatility | |
|---|---|
| PV3B Average Weekly Movement | 16.9% |
| Pharmaceuticals Industry Average Movement | 7.8% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: PV3B's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: PV3B's weekly volatility has decreased from 34% to 17% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1987 | 121 | Jay Duker | eyepointpharma.com |
EyePoint Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 2 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME).
EyePoint Pharmaceuticals, Inc. Fundamentals Summary
| PV3B fundamental statistics | |
|---|---|
| Market cap | €730.27m |
| Earnings (TTM) | -€79.51m |
| Revenue (TTM) | €46.15m |
15.8x
P/S Ratio-9.2x
P/E RatioIs PV3B overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PV3B income statement (TTM) | |
|---|---|
| Revenue | US$50.39m |
| Cost of Revenue | US$78.02m |
| Gross Profit | -US$27.63m |
| Other Expenses | US$59.19m |
| Earnings | -US$86.82m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.27 |
| Gross Margin | -54.83% |
| Net Profit Margin | -172.29% |
| Debt/Equity Ratio | 0% |
How did PV3B perform over the long term?
See historical performance and comparison